semaglutide fda approval date Semaglutide: The Drug of Today and a Steppingstone to Tomorrow What's New in Obesity Treatment?

A balanced diet will help you feel your best while losing weight

New CV indication for Wegovy ( NICE, April 2026 ): Adults with cardiovascular diseases like previous heart attack, stroke, or peripheral arterial disease, etc

Persistent lumps or thickened areas (lipohypertrophy) indicate tissue changes from repeated injections in the same spot

This streamlined process eliminates confusion and ensures your 28-day window begins only when you open the vial for your first dose

The interactions between GLP-1 medications and other glucose-lowering agents are complex, and incorrect adjustments can cause dangerous hypoglycemia or hyperglycemia

Body weight was reduced by 9.8% in the semaglutide group compared with 3.4% in the placebo group